SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 134 filers reported holding SAGE THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $56,000 | -27.3% | 771 | +40.2% | 0.00% | -100.0% |
Q3 2019 | $77,000 | -78.1% | 550 | -71.4% | 0.00% | -66.7% |
Q2 2019 | $351,000 | +457.1% | 1,922 | +380.5% | 0.00% | – |
Q1 2019 | $63,000 | +96.9% | 400 | +19.8% | 0.00% | – |
Q4 2018 | $32,000 | -60.5% | 334 | -41.2% | 0.00% | -100.0% |
Q3 2018 | $81,000 | +11.0% | 568 | +24.0% | 0.00% | 0.0% |
Q2 2018 | $73,000 | 0.0% | 458 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $73,000 | +15.9% | 458 | +19.9% | 0.00% | 0.0% |
Q4 2017 | $63,000 | +6200.0% | 382 | +2022.2% | 0.00% | – |
Q3 2017 | $1,000 | 0.0% | 18 | +63.6% | 0.00% | – |
Q2 2017 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | – |
Q1 2017 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | – |
Q4 2016 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | – |
Q3 2016 | $1,000 | – | 11 | -31.2% | 0.00% | – |
Q2 2016 | $0 | -100.0% | 16 | 0.0% | 0.00% | – |
Q1 2016 | $1,000 | -50.0% | 16 | -52.9% | 0.00% | – |
Q4 2015 | $2,000 | +100.0% | 34 | +78.9% | 0.00% | – |
Q3 2015 | $1,000 | 0.0% | 19 | 0.0% | 0.00% | – |
Q2 2015 | $1,000 | – | 19 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |